Compassionate Use Policy

At Ansun, we are committed to developing safe and effective therapies for respiratory infectious diseases in severely ill  patients as quickly as possible. As part of that commitment, we have supported expanded access and compassionate use programs for DAS181.

In the past seven years, over 150 patients suffering from severe respiratory infections have been treated with DAS181 through compassionate use via single patient emergency INDs (eINDs).  Many patients have survived and/or improved their respiratory status after treatment with DAS181. The results from these eINDs were very encouraging. For that reason, Ansun is moving forward with development of DAS181 for hospitalized patients infected with parainfluenza and influenza.

In order to bring DAS181 to this patient population as quickly as possible, Ansun must focus all efforts and resources on planning and executing studies to support the clinical development of DAS181.  Regrettably, we are no longer able to support eIND requests as of September 22, 2017. As a small company, it has become a challenge for us to maintain the eIND program with the limited available personnel and financial resources that we have.

It has been very rewarding for Ansun to be able to help and give hope to patients who are severely ill and suffering from life-threatening infections. We would like to thank all who have been and continue to be involved in the development of DAS181. We wish all the best for your patients and appreciate your understanding regarding this decision. We encourage participation in our formal clinical development programs for DAS181 as applicable for patients in need. For further information regarding this notification, please contact:

Mike Havluciyan

Senior V.P. of Operations, General Counsel

Tel: 858-452-2631 (x186)

mhavluciyan@ansunbiopharma.com